PRA Health Sciences (PRAH) Rating Increased to Buy at BidaskClub

PRA Health Sciences (NASDAQ:PRAH) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

PRAH has been the subject of several other reports. SunTrust Banks boosted their price target on PRA Health Sciences to $120.00 and gave the company a “buy” rating in a research note on Monday, November 5th. UBS Group started coverage on PRA Health Sciences in a research note on Tuesday, October 9th. They issued a “neutral” rating for the company. Evercore ISI started coverage on PRA Health Sciences in a research note on Thursday, October 4th. They issued an “inline” rating and a $120.00 price target for the company. ValuEngine cut PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Finally, Zacks Investment Research cut PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $112.56.

Shares of PRAH stock opened at $97.12 on Friday. The company has a debt-to-equity ratio of 1.22, a current ratio of 0.89 and a quick ratio of 0.89. The company has a market capitalization of $6.25 billion, a P/E ratio of 30.35, a P/E/G ratio of 1.20 and a beta of 1.10. PRA Health Sciences has a 1 year low of $79.20 and a 1 year high of $121.98.



PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings results on Wednesday, October 31st. The medical research company reported $1.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.06. The business had revenue of $717.60 million during the quarter, compared to analysts’ expectations of $729.63 million. PRA Health Sciences had a return on equity of 25.75% and a net margin of 2.37%. The firm’s revenue for the quarter was up 23.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.88 earnings per share. As a group, analysts predict that PRA Health Sciences will post 3.93 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PRAH. Price Capital Management Inc. bought a new position in shares of PRA Health Sciences in the 3rd quarter valued at $121,000. Mount Yale Investment Advisors LLC lifted its stake in shares of PRA Health Sciences by 103.6% in the 2nd quarter. Mount Yale Investment Advisors LLC now owns 1,704 shares of the medical research company’s stock valued at $159,000 after acquiring an additional 867 shares during the last quarter. Parallel Advisors LLC lifted its stake in shares of PRA Health Sciences by 930.9% in the 3rd quarter. Parallel Advisors LLC now owns 1,804 shares of the medical research company’s stock valued at $199,000 after acquiring an additional 1,629 shares during the last quarter. Bremer Trust National Association bought a new position in shares of PRA Health Sciences in the 3rd quarter valued at $205,000. Finally, Gideon Capital Advisors Inc. bought a new position in shares of PRA Health Sciences in the 3rd quarter valued at $207,000. Hedge funds and other institutional investors own 97.23% of the company’s stock.

About PRA Health Sciences

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Featured Article: Earnings Per Share

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply